Grassi C - Search Results

1

Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.

Acocella G, Luisetti M, Grassi GG, Peona V, Pozzi E, Grassi C. Acocella G, et al. Among authors: grassi gg, grassi c. Monaldi Arch Chest Dis. 1993;48(3):205-9. Monaldi Arch Chest Dis. 1993. PMID: 8369784 Clinical Trial.

2

Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose study.

Acocella G, Nonis A, Gialdroni-Grassi G, Grassi C. Acocella G, et al. Among authors: grassi c. Am Rev Respir Dis. 1988 Oct;138(4):882-5. doi: 10.1164/ajrccm/138.4.882. Am Rev Respir Dis. 1988. PMID: 3202464

3

Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study.

Acocella G, Nonis A, Perna G, Patane E, Gialdroni-Grassi G, Grassi C. Acocella G, et al. Among authors: grassi c. Am Rev Respir Dis. 1988 Oct;138(4):886-90. doi: 10.1164/ajrccm/138.4.886. Am Rev Respir Dis. 1988. PMID: 3202465

4

Pharmacokinetic studies on antituberculosis regimens in humans. I. Absorption and metabolism of the compounds used in the initial intensive phase of the short-course regimens: single administration study.

Acocella G, Conti R, Luisetti M, Pozzi E, Grassi C. Acocella G, et al. Among authors: grassi c. Am Rev Respir Dis. 1985 Sep;132(3):510-5. doi: 10.1164/arrd.1985.132.3.510. Am Rev Respir Dis. 1985. PMID: 4037525

5

New drugs for tuberculosis.

Grassi C, Peona V. Grassi C, et al. Eur Respir J Suppl. 1995 Sep;20:714s-718s. Eur Respir J Suppl. 1995. PMID: 8590571 Review.

6

Use of rifabutin in the treatment of pulmonary tuberculosis.

Grassi C, Peona V. Grassi C, et al. Clin Infect Dis. 1996 Apr;22 Suppl 1:S50-4. doi: 10.1093/clinids/22.supplement_1.s50. Clin Infect Dis. 1996. PMID: 8785257 Review.

7

Familial elevation of serum angiotensin converting enzyme activity.

Luisetti M, Martinetti M, Cuccia M, Dugoujon JM, De Rose V, Peona V, Pozzi E, Grassi C. Luisetti M, et al. Among authors: grassi c. Eur Respir J. 1990 Apr;3(4):441-6. Eur Respir J. 1990. PMID: 2163879

8

TB treatment: yesterday, today and ... tomorrow.

Grassi C, Peona V. Grassi C, et al. Monaldi Arch Chest Dis. 1994 Sep;49(4):283-4. Monaldi Arch Chest Dis. 1994. PMID: 8000409 No abstract available.

9

MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial.

Luisetti M, Sturani C, Sella D, Madonini E, Galavotti V, Bruno G, Peona V, Kucich U, Dagnino G, Rosenbloom J, Starcher B, Grassi C. Luisetti M, et al. Among authors: grassi c. Eur Respir J. 1996 Jul;9(7):1482-6. doi: 10.1183/09031936.96.09071482. Eur Respir J. 1996. PMID: 8836663 Free article. Clinical Trial.

10

Studies of MR 889, a new synthetic proteinase inhibitor.

Luisetti M, Piccioni PD, Donnini M, Peona V, Pozzi E, Grassi C. Luisetti M, et al. Among authors: grassi c. Biochem Biophys Res Commun. 1989 Dec 15;165(2):568-73. doi: 10.1016/s0006-291x(89)80004-x. Biochem Biophys Res Commun. 1989. PMID: 2597145

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

517 results

Search Page

Filters